Feed aggregator

AWS SES (Amazon Simple Email Service) is a cloud-based email-sending service that is both reliable and cost-effective. This service is offered by Amazon Web Services. Postfix is a popular email server for Debian and Unix-like systems. It is an open-source Mail Transfer Agent (MTA) responsible for routing and delivering emails. Debian Linux is a widely used Linux distribution known for its stability and user-friendliness for server usage. Let us see how to integrate AWS SES with the Postfix MTA on Debian Linux version 11/12. Love this? sudo share_on: Twitter - Facebook - LinkedIn - Whatsapp - Reddit The post How to configure AWS SES with Postfix MTA on Debian Linux appeared first on nixCraft. 2024-04-19T07:04:06Z 2024-04-19T07:04:06Z Vivek Gite

When you run the sudo apt update, you may see the following message or error on a Debian Linux: Err:5 http://deb.debian.org/debian buster-backports Release 404 Not Found [IP: 146.75.34.132 80] Reading package lists... Done E: The repository 'http://deb.debian.org/debian buster-backports Release' no longer has a Release file. N: Updating from such a repository can't be done securely, and is therefore disabled by default. N: See apt-secure(8) manpage for repository creation and user configuration details. Here is how to fix this issue. Love this? sudo share_on: Twitter - Facebook - LinkedIn - Whatsapp - Reddit The post The repository ‘http://deb.debian.org/debian buster-backports Release’ no longer has a Release file. appeared first on nixCraft. 2024-04-14T20:42:01Z 2024-04-14T20:42:01Z Vivek Gite

You can find the timezone in Linux using the command line. The easiest way to do this is to type the "timedatectl" command and look for the "timezone" line when using modern Linux distros with systemd. There are other commands and ways to temporarily switch to a new timezone for date calculations. Love this? sudo share_on: Twitter - Facebook - LinkedIn - Whatsapp - Reddit The post How do I find out my timezone in Linux? appeared first on nixCraft. 2024-04-06T01:06:44Z 2024-04-06T01:06:44Z Vivek Gite

Experimental code ready for testing to enable HDMI 2.1 FRL with AMDGPU on Linux  GamingOnLinux

Waze is once again teaming up with World of Warcraft, this time bringing a darker presence to your turn-by-turn directions: the Harbinger of the Void, Xal’atath.After th…

Intel Lands Initial Preparations For DSA 3.0 Accelerators In Linux 7.0  Phoronix

NVIDIA recommended driver 580.126.18 released for Linux  GamingOnLinux

An overview of Google’s new global partnerships and funding announcements at the AI Impact Summit in India.An overview of Google’s new global partnerships and funding announcements at the AI Impact Summit in India.

AI isn’t just helping people solve problems faster, it’s unlocking new possibilities for discovery and scalability. To support organizations at the forefront of scientif…

Government AI adoption isn't just a technical upgrade, it's a way to solve real world challenges and drive societal impact for communities. Yet new data reveals that whi…

A look at the partnerships and investments Google announced at the AI Impact Summit 2026.

A look at the partnerships and investments Google announced at the AI Impact Summit 2026.

In a small double-blind clinical trial, a single intravenous dose of DMT produced rapid and clinically meaningful reductions in symptoms of major depressive disorder within a week, with effects lasting up to three months in some patients. "Unlike psilocybin and lysergic acid diethylamide ( LSD), whose effects can last for hours, intravenous DMT has a half-life of around five minutes," notes ScienceAlert. "Its psychedelic effects are correspondingly brief, potentially making it more practical to administer in clinical settings." From the report: "A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to three months," writes a team led by neuroscientists David Erritzoe and Tommaso Barba of Imperial College London. [...] They recruited 34 participants with major depression and divided them into two groups of 17 for a double-blind, placebo-controlled trial. In the first stage of the trial, one group received an intravenous dose of DMT, while the other received an active placebo. Neither the researchers nor the participants were informed which participants received the DMT. The doses took around 10 minutes to administer, and a therapist sat with each participant to ensure comfort and safety while the psychedelic effects were active, remaining silent throughout the treatment. The treatment was generally well tolerated. Most side effects were mild to moderate, and included nausea, temporary anxiety, and pain at the injection site. No serious adverse events related to the treatment were reported, although brief increases in heart rate and blood pressure were observed immediately after dosing. In the second, open-label stage, two weeks after the first dose, all participants were given the opportunity to receive a dose of DMT. Participants were assessed before and at intervals after each dose using the Montgomery-Asberg Depression Rating Scale. Just a week after the first dose, participants who had received DMT had improved scores compared to the placebo group, and improvements were sustained during follow-up assessments. Two weeks after the first dose, the participants who received DMT scored about seven points lower, on average, than those who received a placebo. On this commonly used clinical scale, a drop of that size is generally considered a meaningful reduction in symptom severity. There was no significant difference between patients who received one or two doses of DMT, suggesting a single dose may be sufficient. These effects persisted for up to three months, and some patients remained in remission for at least six months following the treatment. The findings have been published in Nature Medicine.

Read more of this story at Slashdot.

Linus Torvalds tells The Reg how Linux evolved from solo act  theregister.com

New SysUpdate Variant Malware Discovered, Decryption Tool for Linux C2 Traffic Released  gbhackers.com

ByteSnap Design and Digi International launch managed security service for embedded Linux devices  New Electronics

Longtime Slashdot reader walterbyrd shares a report from ABC News: In a study of nearly 28 million older Americans, long-term exposure to fine particle air pollution raised the risk of Alzheimer's disease. That link held even after researchers accounted for common conditions like high blood pressure, stroke and depression. Fine particle air pollution, known as PM2.5, consists of tiny particles in the air that come from car exhaust, power plants, wildfires, and burning fuels, according to the American Lung Association. They are small enough to travel deep into the lungs and even reach the bloodstream. The research, conducted at Emory University and published in PLOS Medicine, tracked health data over nearly two decades to explore whether air pollution harms the brain indirectly by causing high blood pressure or heart disease, which, in turn, leads to dementia. However, these "middleman" conditions accounted for less than 5% of the connection between pollution and Alzheimer's, the research found. The researchers say this suggests that over 95% of the Alzheimer's risk comes from the direct impact of breathing in dirty air, likely through inflammation or damage to brain cells. "The relationship between PM2.5 and AD [Alzheimer's disease] has been shown to be pretty much linear," said Kyle Steenland, a professor in the departments of environmental health and epidemiology at the Rollins School of Public Health at Emory University, and senior author of the study. "The reason this is particularly important is that PM2.5 is known to be associated with high blood pressure, stroke and depression -- all of which are associated with AD. So, from a prevention standpoint, simply treating these diseases will not get rid of the problem. We have to address exposure to PM2.5."

Read more of this story at Slashdot.

8 Years Later, Linux-based AsteroidOS 2.0 is Here to Add New Life to Your Old Smartwatch  It's FOSS

Everyone uses open source, but patching still moves too slowly  Help Net Security

LockBit 5.0 ransomware targets Windows, Linux, ESXi  IT Brief UK

An anonymous reader quotes a report from the Associated Press: Agrochemical maker Bayer and attorneys for cancer patients announced a proposed $7.25 billion settlement Tuesday to resolve thousands of U.S. lawsuits alleging the company failed to warn people that its popular weedkiller Roundup could cause cancer. The proposed settlement comes as the U.S. Supreme Court is preparing to hear arguments in April on Bayer's assertion that the U.S. Environmental Protection Agency's approval of Roundup without a cancer warning should invalidate claims filed in state courts. That case would not be affected by the proposed settlement. But the settlement would eliminate some of the risk from an eventual Supreme Court ruling. Patients would be assured of receiving settlement money even if the Supreme Court rules in Bayer's favor. And Bayer would be protected from potentially larger costs if the high court rules against it. Germany-based Bayer, which acquired Roundup maker Monsanto in 2018, disputes the assertion that Roundup's key ingredient, glyphosate, can cause non-Hodgkin lymphoma. But the company has warned that mounting legal costs are threatening its ability to continue selling the product in U.S. agricultural markets. "Litigation uncertainly has plagued the company for years, and this settlement gives the company a road to closure," Bayer CEO Bill Anderson said Tuesday. The proposed settlement could total up to $7.25 billion over 21 years and resolve most of the remaining U.S. lawsuits surrounding the cancer-related harms of Roundup. The report notes that more than 125,000 claims have been filed since 2015, and while many have already been settled, this deal aims to cover most outstanding and future claims tied to past exposure. Individual payouts would vary widely based on exposure type, age at diagnosis, and cancer severity. Bayer can also cancel the deal if too many plaintiffs opt out.

Read more of this story at Slashdot.